AngioDynamics Launches AMBITION BTK Trial for Critical Limb Ischemia Treatment Using Auryon Laser Technology
核心洞察
AngioDynamics has enrolled the first patient in the AMBITION BTK randomized controlled trial, investigating the Auryon Atherectomy System (搜索) combined with balloon angioplasty versus balloon angioplasty alone for below-the-knee critical limb ischemia (搜索).
The trial will include up to 224 patients at 30 sites, with a companion registry enrolling up to 1,500 additional patients, addressing a critical need as untreated CLI carries a 20-25% risk of limb loss at one year.
The Auryon laser system uses 355nm wavelength solid-state technology to treat arterial occlusions and has already been used in over 100,000 patients worldwide, offering potential improvements for challenging below-the-knee lesions.
AngioDynamics has achieved a significant milestone in peripheral artery disease (搜索) research by enrolling the first patient in the AMBITION BTK trial, a randomized controlled study investigating the Auryon Atherectomy System (搜索) for treating critical limb ischemia (搜索) below the knee. The first patient was treated by Dr. Anahita Dua, a vascular surgeon at Massachusetts General Hospital and associate professor of Surgery at Harvard Medical School.
Trial Design and Objectives
The AMBITION BTK study is a prospective, multicenter, randomized controlled trial designed to investigate the clinical safety and effectiveness of the Auryon Atherectomy System (搜索) combined with standard balloon angioplasty, compared to balloon angioplasty alone, in treating infrapopliteal lesions in patients with Critical Limb Ischemia (搜索) (CLI).
The trial will enroll up to 224 patients across up to 30 sites, with the primary endpoint evaluated using a win-ratio approach at 12 months. The hierarchical comparison between treatment groups will assess freedom from major amputation, freedom from clinically driven target lesion revascularization (CD-TLR), and primary patency. Additionally, a companion registry will enroll up to 1,500 patients who are ineligible for the RCT and are treated with the Auryon System above or below the knee.
Addressing Critical Medical Need
The clinical significance of this trial becomes apparent when considering the devastating impact of untreated CLI. The overall risk of limb loss in CLI is estimated at 20-25% at one year if left untreated, reflecting a substantial impact on quality of life and healthcare costs. The incidence of infrapopliteal disease (搜索) in patients with CLI, particularly in the diabetic population, is estimated to be greater than 70%.
"Across the world, there has been a significant increase in patients with below-the-knee (BTK) disease, which is, unfortunately, resulting in an amputation epidemic," said Dr. Dua. "Having new tools and techniques to restore blood flow to the foot, allowing wounds to heal, and patients to preserve both their limbs and lives, is critically important and the focus of this trial."
Current Treatment Limitations
The trial addresses significant gaps in current treatment approaches for below-the-knee lesions. According to AMBITION BTK Co-Principal Investigator Dr. Ehrin Armstrong, an interventional cardiologist and director of clinical research at Advanced Heart and Vein Center (搜索), "Treatment options for below-the-knee lesions are still limited and often depend heavily on balloon angioplasty. The Auryon laser can restore laminar flow and therefore has the potential to improve outcomes in this challenging patient population significantly."
Auryon Atherectomy System Technology
The Auryon Atherectomy System (搜索) represents a technological advancement in treating arterial occlusions. The system is the first laser atherectomy system designed to efficiently treat any lesion type, any lesion length, at any lesion location, with minimal impact on vessel walls. The device uses solid-state laser technology and is FDA cleared for treatment, including atherectomy, of infrainguinal stenoses and occlusions, including in-stent restenosis.
The system's targeted biological reactions minimize the risk of perforation and preserve the ability to vaporize lesions without thermal ablation. The Auryon System uses a 355nm wavelength laser platform which enables the use of longer wavelengths and shorter pulses to produce short UV laser pulses. To date, the Auryon laser has been used to treat more than 100,000 patients in the United States and worldwide.
Clinical Impact and Future Implications
Laura Piccinini, Senior Vice President/General Manager, Cardiovascular & International at AngioDynamics, emphasized the trial's significance: "The enrollment of the first patient in the AMBITION BTK trial is a significant milestone in our commitment to advancing clinical evidence for the treatment of below-the-knee peripheral artery disease (搜索) (PAD). There is a pressing need for new treatment strategies to help patients suffering from chronic limb ischemia."
Dr. Dua highlighted the trial's potential to generate crucial evidence: "This trial will allow us to collect high-quality, real-world data using a robust research design, helping us truly evaluate the impact of laser technology in BTK disease."
The Auryon laser system's versatility extends beyond below-the-knee applications, as it can treat all infrainguinal lesion types, including above-the-knee (ATK), BTK, and in-stent restenosis, positioning it as a comprehensive solution for peripheral artery disease (搜索) management.